PURPOSE: To determine the glaucoma phenotype of an American pedigree with the myocilin Asp380His. DESIGN: An observational case series study. METHODS: An observational case series study was used to examine a family in which an Asp380His myocilin mutation was segregating. Thirteen family members were examined and medical records were obtained on the remaining two individuals. Blood samples were collected from all 15 participants following the tenets of the Helsinki declaration under the auspices of the Oregon Health & Sciences University Institutional Review Board and screened for myocilin variants by denaturing high-performance liquid chromatography (dHPLC). Any DNA samples with dHPLC data different from the control sample were sequenced for base pair analysis. RESULTS: An Asp380His myocilin mutation was identified in eight members, seven of whom had primary open-angle glaucoma (POAG). The eighth individual had high intraocular pressures (IOPs). The disease presents in this family with extremely high IOPs requiring trabeculectomies to control the pressure. The age at diagnosis ranged from 30 to 45. CONCLUSIONS: This family with an Asp380His myocilin mutation presents with an intermediate phenotype between juvenile- and adult-onset glaucoma. The Asp380 amino acid residue appears to be important in myocilin function based on the finding that substitution of this amino acid with four different amino acids (His, Ala, Asn, or Gly) all result in a similar presentation of POAG that is intermediate between the more severe clinical presentations observed in individuals with the Pro370Leu or Lys423Glu variant and the milder findings in patients with the Gln368Stop mutation.
PURPOSE: To determine the glaucoma phenotype of an American pedigree with the myocilinAsp380His. DESIGN: An observational case series study. METHODS: An observational case series study was used to examine a family in which an Asp380Hismyocilin mutation was segregating. Thirteen family members were examined and medical records were obtained on the remaining two individuals. Blood samples were collected from all 15 participants following the tenets of the Helsinki declaration under the auspices of the Oregon Health & Sciences University Institutional Review Board and screened for myocilin variants by denaturing high-performance liquid chromatography (dHPLC). Any DNA samples with dHPLC data different from the control sample were sequenced for base pair analysis. RESULTS: An Asp380Hismyocilin mutation was identified in eight members, seven of whom had primary open-angle glaucoma (POAG). The eighth individual had high intraocularpressures (IOPs). The disease presents in this family with extremely high IOPs requiring trabeculectomies to control the pressure. The age at diagnosis ranged from 30 to 45. CONCLUSIONS: This family with an Asp380Hismyocilin mutation presents with an intermediate phenotype between juvenile- and adult-onset glaucoma. The Asp380 amino acid residue appears to be important in myocilin function based on the finding that substitution of this amino acid with four different amino acids (His, Ala, Asn, or Gly) all result in a similar presentation of POAG that is intermediate between the more severe clinical presentations observed in individuals with the Pro370Leu or Lys423Glu variant and the milder findings in patients with the Gln368Stop mutation.
Authors: R Kubota; Y Mashima; Y Ohtake; T Tanino; T Kimura; Y Hotta; A Kanai; S Tokuoka; I Azuma; H Tanihara; M Inatani; Y Inoue; J Kudoh; Y Oguchi; N Shimizu Journal: Hum Mutat Date: 2000-09 Impact factor: 4.878
Authors: S Shimizu; P R Lichter; A T Johnson; Z Zhou; M Higashi; M Gottfredsdottir; M Othman; S E Moroi; F W Rozsa; R M Schertzer; M S Clarke; A L Schwartz; C A Downs; D Vollrath; J E Richards Journal: Am J Ophthalmol Date: 2000-08 Impact factor: 5.258
Authors: J E Craig; P N Baird; D L Healey; A I McNaught; P J McCartney; J L Rait; J L Dickinson; L Roe; J H Fingert; E M Stone; D A Mackey Journal: Ophthalmology Date: 2001-09 Impact factor: 12.079
Authors: Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass Journal: Arch Ophthalmol Date: 2002-06
Authors: Andrea L Vincent; Gail Billingsley; Yvonne Buys; Alex V Levin; Megan Priston; Graham Trope; Donna Williams-Lyn; Elise Héon Journal: Am J Hum Genet Date: 2002-01-03 Impact factor: 11.025
Authors: Chi Pui Pang; Yuk Fai Leung; Baojian Fan; Larry Baum; Win Chi Tong; Wing Shan Lee; John K H Chua; Dorothy S P Fan; Yao Liu; Dennis S C Lam Journal: Invest Ophthalmol Vis Sci Date: 2002-10 Impact factor: 4.799
Authors: Mary K Wirtz; John R Samples; Victoria Toumanidou; Jac Charlesworth; Dimitrios G Mikropoulos; Konstantinos Kaltsos; Athanasios Economou; Antonios Dimopoulos; Irene N Georgiadou; Georgios Moumtzis; Athanasios Papanastasiou; Patricia L Kramer; Tom Dyer; John Blangero; Anastasios G P Konstas Journal: Invest Ophthalmol Vis Sci Date: 2010-01-27 Impact factor: 4.799
Authors: Mary K Wirtz; Anastasios G P Konstas; John R Samples; Kostantinos Kaltsos; Athanasios Economou; Antonios Dimopoulos; Irene Georgiadou; Michael B Petersen Journal: Mol Vis Date: 2008-04-25 Impact factor: 2.367